HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
6 hedge funds and large institutions have $824K invested in HOOKIPA Pharma in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 23 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
39.8% less ownership
Funds ownership: 48.91% → 9.11% (-40%)
78% less funds holding
Funds holding: 27 → 6 (-21)
86% less capital invested
Capital invested by funds: $6.01M → $824K (-$5.18M)
91% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 23
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$365K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$19K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gilead Sciences
Foster City,
California
|
-$2.35M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.02M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$711K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$419K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$378K |
HOOK Hedge Fund Activity: Q3 2025 in Review
6 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q3 2025, worth a combined $824K — down 86% from $6.01M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of HOOK and 2 opened new positions — a net loss of 21 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was JBF Capital, opening a new position worth an estimated $365K. The largest seller was Gilead Sciences, exiting entirely with an estimated $2.35M sold.
- 6 institutional investors held HOOKIPA Pharma (HOOK) as of Q3 2025, down from 27 in Q2 2025.
- Funds reported $824K of HOOKIPA Pharma stock for Q3 2025, down 86% quarter-over-quarter.
- 2 funds opened new HOOKIPA Pharma positions in Q3 2025 and 23 closed out, a net change of -21 holders.
- The largest HOOKIPA Pharma buyer in Q3 2025 was JBF Capital, an estimated $365K added.
- The largest HOOKIPA Pharma seller in Q3 2025 was Gilead Sciences, an estimated $2.35M sold.
Based on aggregated 13F filings for Q3 2025.